CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.–(BUSINESS WIRE)–$CVM #Multikine–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share.
